Wexford Capital’s AbbVie ABBV Stock Holding History

Wexford Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,000	Closed	-$1.03M	–	167
2024 Q2	$1.03M	Hold	6,000	–	–	0.26%	63
2024 Q1	$1.09M	Buy	+6,000	New	+$1.03M	0.22%	81
2023 Q3	–	Sell	-3,619	Closed	-$488K	–	184
2023 Q2	$488K	Buy	+3,619	New	+$531K	0.1%	113
2021 Q1	–	Sell	-29,424	Closed	-$3.15M	–	191
2020 Q4	$3.15M	Sell	29,424 -78,265	-73%	-$7.52M	0.49%	55
2020 Q3	$9.43M	Buy	107,689 +18,660	+21%	+$1.76M	2.52%	8
2020 Q2	$8.74M	Buy	+89,029	New	+$7.84M	2.2%	13
2016 Q3	–	Sell	-32,958	Closed	-$2.04M	–	158
2016 Q2	$2.04M	Buy	32,958 +19,740	+149%	+$1.2M	0.35%	61
2016 Q1	$755K	Sell	13,218 -41,265	-76%	-$2.3M	0.15%	81
2015 Q4	$3.23M	Sell	54,483 -54,407	-50%	-$3.13M	0.76%	35
2015 Q3	$5.92M	Buy	+108,890	New	+$7.09M	1.15%	36
2014 Q4	–	Sell	-25,000	Closed	-$1.44M	–	51
2014 Q3	$1.44M	Buy	+25,000	New	+$1.39M	0.13%	72

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wexford Capital's ABBV Position: Q3 2024 in Review

Wexford Capital sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 6,000 shares — an estimated $1.03M sold.

Wexford Capital first reported a position in ABBV in Q3 2014 and held it in 11 quarters. The position peaked at $9.43M in Q3 2020. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Wexford Capital reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
Wexford Capital sold 6,000 AbbVie shares in Q3 2024, an estimated $1.03M.
Wexford Capital first reported a position in AbbVie in Q3 2014 and held it in 11 quarters.
Wexford Capital's AbbVie position peaked at $9.43M in Q3 2020.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Wexford Capital's 13F filing for Q3 2024, filed 14 Nov 2024.